

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



北京健康(控股)有限公司
Beijing Health (Holdings) Limited

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 2389)

PROFIT WARNING

This announcement is made by Beijing Health (Holdings) Limited (the “**Company**”, together with its subsidiaries as the “**Group**”) pursuant to Rule 13.09(2)(a) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”) and the Inside Information Provisions (as defined under the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Cap. 571, Laws of Hong Kong).

The board of directors (the “**Board**”) of the Company wishes to inform the shareholders and potential investors of the Company that based on the preliminary assessment of the Group’s unaudited consolidated management accounts for the year ended 31 December 2024 and the information currently available to the Company, it is expected that loss attributable to the owners of the Company of the Group for the year ended 31 December 2024 will increase by approximately HK\$55,000,000 as compared with the corresponding period in 2023. During the year, the Group’s day-to-day operations remained relatively stable and the increase in loss was mainly due to the net increase in the following expenses:

- (1) Exchange losses of approximately HK\$29,290,000 were recorded during the year due to the depreciation of CAD and RMB, and exchange gains of approximately HK\$9,237,000 were recorded for the corresponding period of the previous year;
- (2) The share price of listed associates held by the Group decreased during the year. The Group performed an impairment assessment and provision for impairment was approximately HK\$11,539,000, and reversal for impairment was approximately HK\$1,211,000 for the corresponding period of the previous year;
- (3) The loss attributable to joint ventures recognized for the year increased by HK\$7,718,000, which is mainly due to the increase in interest expenses of joint ventures resulted from the increase in interest rates; and
- (4) An impairment of approximately HK\$14,165,000 was made on an other receivable in the previous year, and similar impairment of assets during the year was approximately HK\$5,000,000.

As at the date of this announcement, the Company is still in the process of finalizing its annual results for the year ended 31 December 2024. The information contained in this announcement is only a preliminary assessment by the Board based on the unaudited consolidated management accounts of the Group, and may be subject to final revisions and other review adjustments on impairment of assets (if any), final share of profits/losses of associates, fair value of investment properties during the review process.

The details of the annual results of the Group for the year ended 31 December 2024 will be disclosed in the annual results announcement of the Company, which is expected to be published on 28 March 2025.

Shareholders and potential investors of the Company are advised to exercise caution when dealing in the shares of the Company.

By Order of the Board of
Beijing Health (Holdings) Limited
Zhu Shi Xing
Chairman

Hong Kong, 14 March 2025

As at the date of this announcement, the Board comprises five executive Directors, namely Mr. Zhu Shi Xing, Mr. Liu Xue Heng, Mr. Gu Shan Chao, Mr. Siu Kin Wai and Mr. Wang Zheng Chun and four independent non-executive Directors, namely Mr. Tse Man Kit, Keith, Mr. Wu Yong Xin, Mr. Zhang Yun Zhou and Ms. Yang Xiao Yan.